Dexmedetomidine After Cardiac Surgery for Prevention of Delirium

ICU Delirium Clinical Trial

— EXACTUM  

Official title:

Dexmedetomidine After Cardiac Surgery for Prevention of Delirium: The Exactum Study a Randomised Double Blind Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03477344
• Other study ID #: 29BRC18.0051 (EXACTUM)
• Status: Completed
• Phase: Phase 3
• Start date: January 4, 2019
• Est. completion date: June 29, 2021

Study information

• Verified date: June 2022
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We designed a prospective, double blind, randomized, controlled versus placebo study to evaluate the efficacy of nightly low dose of Dexmedetomidine infusion to promote sleep and lower delirium in a population of post cardiac surgery patients. This population is characterized by longer ICU stay, more physical restraints such as catheters and drains, pain and sleep deprivation. It is associated with higher prevalence of Delirium and agitation leading to exposure to severe agitation related adverse events.

Description:

Delirium occurs in about 25% of patients after cardiac surgery. It is an independent factor of poor outcome and recovery after ICU stay as it is associated with mortality and impaired mental function one year after its onset. It is associated with increased public health costs during the hospital stay and after.

The use of Dexmedetomidine as sedative medication is more and more described. It is well established that it can lower delirium onset comparatively to Midazolam or Propofol. It is also useful in agitated delirium as a complementary medication to reduce delirium duration. A study published by Su et al in 2016 assessed the efficacy of Dexmedetomidine in prevention of post-surgical delirium for patients older than 65 years after non cardiac surgery. Patients were mainly admitted in the ICU after abdominal surgery for malignant tumor. Dexmedetomidine was used at very low dose to promote sleep during ICU stay. In this study the onset of delirium was significantly lowered by one half for the first week after surgery. However, this study only focused on older patients and non-cardiac surgery population with short mechanical ventilation duration, short ICU stay and low incidence of complications.

We designed a prospective, double blind, randomized, controlled versus placebo study to evaluate the efficacy of nightly low dose of Dexmedetomidine infusion to promote sleep and lower delirium in a population of post cardiac surgery patients. This population is characterized by longer ICU stay, more physical restraints such as catheters and drains, pain and sleep deprivation. It is associated with higher prevalence of Delirium and agitation leading to exposure to severe agitation related adverse events. In the study by Su and al low dose Dexmedetomidine did not induce adverse events such as bradycardia or hypotension, conversely safety outcomes showed that Dexmedetomidine use was associated with fewer tachycardia and hypoxaemia. Moreover, data shows that Dexmedetomidine is likely to play a cardio protective role in the same way as Clonidine. Those findings are encouraging for its use after cardiac surgery.

Delirium will be assessed by the Confusion Assessment Method for the ICU (CAM ICU) and the primary endpoint of the study is the occurrence of delirium in the first 7 days following surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 348
• Est. completion date: June 29, 2021
• Est. primary completion date: June 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• patients aged 65 or more who undergo cardiac surgery on and off-pump: coronary artery bypass graft, cardiac valve replacement or both.

• Consent signed

Exclusion Criteria:

• history of mental illness, dementia

• inclusion in another study evaluating sedation or pain

• length of stay in ICU less than 24 hours

• alpha 2 agonists allergy

• surgery performed in an immediate emergency situation

• uncontrolled hypotension

• second and third degree atrioventricular block without pacemaker

• severe hepatic insufficiency

• acute cerebrovascular diseases

• patient treated with clonidine

• patient with disturbed preoperative liver assessment (hepatocellular insufficiency)

• patient under guardianship or curatorship

Related Conditions & MeSH terms

• Delirium
• ICU Delirium

Intervention

Drug:
• Dexmedetomidine
Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
• Sodium chloride 0.9%
Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.

Locations

Country	Name	City	State
France	Angers university hospital	Angers
France	CHRU de Brest	Brest
France	Clermont Ferrand university hospital	Clermont-Ferrand
France	CHU de Grenoble	Grenoble
France	Hôpital Privé Jacques Cartier	Massy
France	CHU de Nantes	Nantes
France	CHU la Pitié Salpétrière	Paris
France	CHU Poitiers	Poitiers
France	CHU de Rennes	Rennes

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Brest	Baxter Healthcare Corporation, Direction Générale de l'Offre de Soins

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Delirium	Occurrence of delirium diagnosed by the Confusion Assessment Method (CAM ICU) at any time in the first seven days after surgery	7 days
Secondary	agitation with be assessed using the Richmond agitation and sedation score	Score Term Description; 4 Combative Overtly combative or violent; immediate danger to staff; 3 Very agitated Pulls on or removes tube(s) or catheter(s) or has aggressive behavior toward staff; 2 Agitated Frequent nonpurposeful movement or patient-ventilator dyssynchrony; 1 Restless Anxious or apprehensive but movements not aggressive or vigorous 0 Alert and calm Spontaneously pays attention to caregiver; 1 Drowsy Not fully alert, but has sustained (more than 10 seconds) awakening, with eye contact, to voice; 2 Light sedation Briefly (less than 10 seconds) awakens with eye contact to voice; 3 Moderate sedation Any movement (but no eye contact) to voice; 4 Deep sedation No response to voice, but any movement to physical stimulation; 5 Unarousable No response to voice or physical stimulation	7 days
Secondary	length of ICU stay	Lenght of patient's ICU stay	28 days
Secondary	length of hospital stay	Length of Patient's hospital stay	28 days
Secondary	quality of life 3 months after surgery with the The Short Form (36) Health Survey score	The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and an abbreviated variant of it, the SF-6D, is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The original SF-36 came out from the Medical Outcome Study, MOS, done by the RAND Corporation. Since then a group of researchers from the original study released a commercial version of SF-36 while the original SF-36 is available in public domain license free from RAND.	90 days
Secondary	cognitive capacity 3 months after surgery evaluated with the Cognitive Failures Questionnnaire (CFQ)	The Cognitive Failures Questionnaire is a self-report scale that taps failures in everyday actions, perception and attention, and memory over the last month. It consists of 25 items that are scored on a 5-point scale (0=never; 4=very often). Illustrative items are 'Do you fail to notice signposts on the road?' and 'Do you forget where you put something like a newspaper or a book?' Scores are summed to obtain a total CFQ score varying from 0 to 100, with higher scores indicating more self-reported cognitive failures.	90 days
Secondary	agitation related adverse events onset and number	-self-extubation	7 days
Secondary	agitation related adverse events onset and number	-catheter or medical devices removal (drains, urinary catheter, arterial and central venous catheters, externenal pacemaker)	7 days
Secondary	agitation related adverse events onset and number	-fall of bed	7 days
Secondary	agitation related adverse events onset and number	-getaway	7 days
Secondary	agitation related adverse events onset and number	-contention removal	7 days
Secondary	agitation related adverse events onset and number	-aggressive acts	7 days
Secondary	Self-assessment of sleep quality	Assessment by a numerical scale from 0 to 10 and the Leeds Sleep questionnaire	7 days
Secondary	Intra hospital mortality and Mortality at 3 months of surgery		3 months
Secondary	Cognitive capacity	Cognitive capacity assessed by Cognitive Failures Questionnaire (CFQ) at 3 months of surgery	3 months
Secondary	Post-traumatic stress disorder	Post-traumatic stress disorder assessed by the PCL-5 questionnaire at 3 months of surgery	3 months